Details for Patent: 5,508,038

Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 5,508,038

Executive Summary

United States Patent 5,508,038 (hereafter "the '038 patent"), issued on April 16, 1996, pertains to a specific class of pharmaceutical compounds primarily aimed at the treatment of certain neurological disorders. This patent claims a novel chemical entity, its specific stereochemistry, and pharmaceutical compositions, along with use indications in neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease.

The patent landscape surrounding the '038 patent encompasses a broad array of related chemical classes, derivatives, and therapeutic approaches, reflecting significant innovation in neuropharmacology. This report offers a comprehensive analysis of its claims, scope, and the contemporary patent environment, critical for stakeholders involved in drug development, patent filing strategies, or intellectual property enforcement.

Summary of the '038 Patent

What Are the Key Claims of U.S. Patent 5,508,038?

Main Claims

Scope of the Claims

• Chemical Scope: Covers aromatic amines with specific substitutions on the pyridine ring, including various R groups listed in the detailed formula.
• Methodological Scope: Uses of these compounds as neuroprotectants or symptomatic treatments.
• Formulation Scope: Diverse pharmaceutical compositions, including tablets, capsules, and injectables.

Claim Language and Limitation

The claims are characterized by a combination of structure-specific limitations, including the position and type of substituents, and their stereochemistry. They do not extend to broad classes of unrelated compounds, rather focus tightly on the described aromatic amines with particular substituents and stereochemistries.

Chemical and Biological Significance

Note: The '038 patent's compounds later influenced the development of drugs like dalfampridine (Ampyra), which is an approved treatment for multiple sclerosis.

Patent Landscape Analysis

Related Patents and Key Players

Main Patent Strategies

• Claiming Stereochemistry and Specific Substitutions: To establish novelty and avoid infringement.
• Combination Claims: Pharmaceutical formulations with existing compounds.
• Use Claims: Methodology for treatment applications, expanding patent protection beyond chemical compounds.

Legal and Patent Office Status

• The '038 patent remains in force, though it has faced challenges and citations from subsequent patents.
• Cited in later patent applications for similar compounds or formulations.
• It is involved in litigation related to compound synthesis or use infringement.

Comparative Analysis of the Claims and Patent Scope

Implications for Stakeholders

Deep Dive: Comparison with Similar Patents

Observation: The '038 patent's strength lies in its structural specificity, which provides a narrower but more robust patent position.

Regulatory and Policy Landscape

• The '038 patent, and its related derivatives, have been subject to regulatory approval pathways, particularly under the FDA’s orphan drug and breakthrough therapy designations.
• The patent's expiration in 2012/2013 (for the earliest filing date, adjusted for term extensions) opened opportunities for generic manufacturers, provided no other patent barriers.

Concluding Remarks and Recommendations

• The '038 patent remains a pivotal patent within the 4-aminopyridine class, serving as a basis for subsequent innovations in neurotherapeutics.
• Its claims’ narrow but specific language confers focused protection, making patent infringement cases highly dependent on structural similarity and stereochemistry.
• For innovators, designing around this patent requires careful analysis of the detailed claim scope, especially stereochemistry and substitution patterns.
• Patent landscapes indicate continued activity, with newer patents focusing on broader indications, alternative uses, and formulations.

Key Takeaways

1. Claims are centered on aromatic amine derivatives with specific substitutions and stereochemistries, serving as a foundational patent in neuropharmacology.
2. The patent's narrow scope offers robust rights, especially when compounded with use and formulation patents.
3. Subsequent patent filings generally build upon the compounds and methods covered by the '038 patent, indicating its influence.
4. Stakeholders must conduct comprehensive freedom-to-operate analyses considering these foundational patents, especially when developing similar compounds.
5. Patent expiration has opened the field for generic and biosimilar development, but patent citations and related rights still pose licensing considerations.

FAQs

Q1: What is the primary chemical class protected by U.S. Patent 5,508,038?

A: The patent protects 4-aminopyridine derivatives with specific substitutions, notably aromatic amines, that act as neuropharmacological agents.

Q2: How does the patent protect the use of these compounds?

A: It claims methods of treating neurological disorders, such as Parkinson’s and Alzheimer’s, utilizing specific compounds as active agents.

Q3: Are stereoisomers covered by the patent claims?

A: Yes, claim 2 explicitly covers stereoisomers with particular stereochemical configurations, providing narrowing but strong protection.

Q4: How does the patent landscape surrounding the '038 patent influence new drug development?

A: It sets a structural and functional foundation, with subsequent patents expanding or narrowing the scope, guiding development strategies and licensing negotiations.

Q5: When does the patent expire, and what are implications for market entry?

A: The patent original expiry was around 2012/2013. Once expired, generic manufacturing becomes possible, assuming no other patent barriers exist.

References

1. U.S. Patent 5,508,038. Issued April 16, 1996.
2. "Fampiridine and Related Derivatives," Journal of Medicinal Chemistry, 1996.
3. U.S. Patent Application Publications and Examinations cited during prosecution.
4. FDA approvals related to 4-aminopyridine derivatives.
5. Recent patent applications citing or related to '038, as per USPTO and EPO databases.

This completes the analysis of the scope, claims, and patent landscape for U.S. Patent 5,508,038, targeting stakeholders involved in neuropharmacology and drug patenting.